Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Pediatrics/Neonatology
Disease Category: Obsessive-Compulsive Disorders
Trial Information
The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the obsessive-compulsive disorder (OCD) of adult patients who have not responded to their OCD medication.
The purpose of this study is to determine whether memantine
(Namenda), in doses up to 20 mg/day, will be effective in treating
the obsessive-compulsive disorder (OCD) of adult patients who have
not responded to their OCD medication. Memantine is not FDA
approved for OCD, but is approved for the treatment of Alzheimer’s
Disease. Memantine appears to work by regulating the activity of
glutamate, one of the brain’s specialized messenger chemicals,
which may play a role in OCD. All patients in the study will
receive memantine; no one will receive placebo.
Patient Inclusion Criteria
- Adult age 18 and over
- Able to travel to Stanford weekly
- Suffering from moderate to severe obsessive-compulsive
disorder
- Currently taking medication for OCD and receiving inadequate
benefit
Patient Exclusion Criteria
- Receiving psychotherapy for OCD
Nona Gamel, Clinical Research Manager
Stanford University School of Medicine
401 Quarry Road
Stanford, CA 94305-5721
Phone: 650-725-5180
EMail: gamel05@stanford.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
